WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-07 11:13 am Sale |
2025-02-28 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
WELLINGTON MANAGEMENT CO LLP | 35,681 0.000% |
-4,950,295 (-99.28%) |
Filing |
| 2024-11-08 10:52 am Sale |
2024-09-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
WELLINGTON MANAGEMENT CO LLP | 4,985,976 5.860% |
-2,599,245 (-34.27%) |
Filing |
| 2024-02-08 10:18 am Sale |
2023-12-29 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
WELLINGTON MANAGEMENT CO LLP | 7,585,221 8.940% |
-398,221 (-4.99%) |
Filing |
| 2023-01-10 09:23 am Purchase |
2022-12-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
WELLINGTON MANAGEMENT CO LLP | 7,983,442 11.720% |
6,384,676 (+399.35%) |
Filing |
| 2022-02-04 09:24 am Sale |
2021-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
WELLINGTON MANAGEMENT CO LLP | 1,598,766 3.040% |
-1,016,677 (-38.87%) |
Filing |
| 2021-02-04 10:27 am Purchase |
2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
WELLINGTON MANAGEMENT CO LLP | 2,615,443 5.540% |
441,220 (+20.29%) |
Filing |
| 2020-12-10 08:12 am Sale |
2020-11-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX |
WELLINGTON MANAGEMENT CO LLP | 2,174,223 5.320% |
-869,467 (-28.57%) |
Filing |